Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
网页TH17 Cells May Serve as Biomarker in Metastatic Melanoma. By Morgan Bayer. September 28th 2024. TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
The Targeted Pulse: IBI363’s Fast Track Status Set to Transform ...
网页2024年9月15日 — The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. We also cover new data highlighting the efficacy of lenvatinib/pembrolizumab in nccRCC, cost-effectiveness of TKIs for CML, and innovative immunotherapies for T-cell malignancies.
The Targeted Pulse: NKT2152 Sparks Excitement in RCC, …
网页5 天之前 — Phase 1/2 Trial Data on NKT2152 Sparks Excitement for Advanced Kidney Cancer. A novel oral HIF2α inhibitor, NKT2152, has shown promising objective response rates (ORR) in both the overall and dose-escalation populations of patients with previously treated advanced clear cell renal cell carcinoma (RCC).
The Targeted Pulse: Breakthrough Treatments in ... - Targeted …
网页2024年3月4日 — Patients with relapsed ovarian cancer who had previously received a poly-ADP ribose polymerase inhibitor (PARPi) with maintenance olaparib (Lynparza) achieved improved progression-free survival (PFS), regardless of BRCA mutation status after a rechallenge of olaparib according to data from the phase 3b OReO/ENGOT-ov38 study (NCT03106987).
TN0155 and Targeted Therapies Lead to Positive ... - Targeted …
网页2024年5月17日 — TN0155 and targeted therapies lead to positive responses in solid tumors. The combination of TNO155, an allosteric SHP2 phosphatase inhibitor, with either spartalizumab (PDR001) or ribociclib (Kisqali) demonstrated acceptable safety and tolerability across solid tumors in a phase 1b open-label study (NCT04000529) presented by Omar Saavedra ...
The Targeted Pulse: Dostarlimab Achieves 100% ... - Targeted …
网页2024年6月9日 — In clinical trials, dostarlimab continues to show a 100% CR in dMMR rectal cancer, camrelizumab plus rivoceranib improved survival in untreated uHCC, lorlatinib provided durable PFS in ALK+ lung cancer. We also cover the acknowledged BLA for zolbetuximab and the meaningful PFS achieved with ibrutinib/venetoclax in CLL/SLL.
Genomic Profiling Offers a Personalized Approach to Breast …
网页1 天前 — M. Michele Blackwood, MD, FACS. Genomic profiling is a personalized approach that essentially analyzes a tumor's genetic makeup to reveal the specific mutations that drive its growth. With a contrasting approach to that of traditional “one-size-fits-all" therapies and by allowing for better understanding of the cancer's unique makeup, experts ...
New CAR T Therapy Shows Promise in Treating R/R Multiple …
网页2024年9月28日 — A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma with high response rates and manageable adverse effects. Durcabtagene autoleucel (PHE885), a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy, produced high response rates with a manageable safety profile in ...
Datopotamab Deruxtecan Shows Durable Efficacy and …
网页2022年12月15日 — Datopotamab deruxtecan (DS-1062a) demonstrated promising and long-lasting efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low, or HER2-negative unresectable or metastatic breast cancer. 1. These results come from a 41-patient cohort of a phase 1, multicenter, first-in-human study (TROPION-PanTumor01; NCT03401385).
Evolving First-Line Treatment Strategies in Metastatic RCC: Key …
网页4 天之前 — EP: 1. Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making. EP: 2. Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC. How has the first-line treatment landscape for metastatic renal cell …